Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360

Alzheimer's Disease (AD) Progressive Supranuclear Palsy (PSP) Cortical Basal Syndrome (CBS) +1 more

COMPLETED EARLY_PHASE1

Tau Imaging in Young Onset Dementia

NCT02289118

Alzheimer's Disease, Early Onset Logopenic Progressive Aphasia Posterior Cortical Atrophy (PCA)

COMPLETED

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03080051

Progressive Supranuclear Palsy Alzheimer Disease Healthy Volunteers

COMPLETED EARLY_PHASE1

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894

Alzheimer's Disease (AD) Parkinson's Disease (PD) Chronic Traumatic Encephalopathy (CTE) +4 more

COMPLETED PHASE1

PET Tau - Neurodegenerative Disease Imaging

NCT03143374

Neurodegenerative Disease

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease (AD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[18F]T807

At the \[18F\]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of \[18F\]T807

Group Type EXPERIMENTAL

[18F]T807

Intervention Type DRUG

All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]T807

All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amyvid [18F]florbetapir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For all Subjects:

* Written informed consent or assent is obtained
* Female subjects/volunteers must be either surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they are of childbearing potential, must commit to the use of two effective contraception methods for the duration of the study.
* Male subjects/volunteers and their partners of childbearing potential must commit to the use of two effective methods of contraception, one of which should be a barrier method for male subjects.

Prodromal and Mild Alzheimer's Disease Subjects

* Males and females aged between 50 and 90 years.
* Study partner has noticed a recent gradual decrease in the subject's memory (e.g., over the prior 12 months), which the subject may or may not be aware of.
* For prodromal subjects, abnormal memory function at screening or 4 weeks prior to screening based on the FCSRT-IR of:Free recall \<17, or Total recall \<40, or Free recall \<20 and total recall \<42.
* Individuals with mild AD must meet the criteria based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association and Diagnostic and Statistical Manual of Mental Disorders, Version 5, criteria. This evidence may be compiled during screening but must be fully documented in the subject's study file before the baseline visit.
* Have an MMSE (Folstein et al. 1975) score at screening \>20.
* Have an Amyvid (florbetapir F 18 injection) scan at screening that demonstrates amyloid binding based on qualitative analysis (visual read) that meets the criteria for AD.
* Modified Hachinski Ischemia Scale (Moroney et al. 1997) score of ≤ 4.

Exclusion Criteria

* Medications taken for symptomatic treatment of AD must be maintained on a stable dosage regimen for at least 4 weeks before the \[18F\]T807 imaging visit.
* Able to participate in all scheduled evaluations.
* The subject has an appropriate caregiver or community dwelling with a caregiver capable of accompanying the subject on all visits to the center as judged by the investigator.
* In the opinion of the investigator, the subject and caregiver will be compliant and have a high probability of completing the study.

Healthy Volunteers

* Males and females aged between 20 and 90 years. Younger healthy controls will be aged 20-49 and older healthy controls will be aged 50-90.
* Healthy volunteers with no clinically relevant findings on physical examination at screening and upon reporting for the \[18F\]T807 imaging visit.
* No suspicion of cognitive impairment/early dementia from MMSE as judged by the investigator (MMSE\>28).
* No concomitant medications, over-the-counter, supplement, or any other agent intended to improve cognition or prevent cognitive decline
* A negative Amyvid (florbetapir F 18 injection) scan at screening based on qualitative analysis (visual read).

For All subjects:

* Current or prior history of any alcohol or drug abuse.
* Severe systemic disease based on history and physical examination.
* Positive result on urine screen for illicit drugs.
* Laboratory tests with clinically significant abnormalities
* Clinically significant unstable medical or psychiatric illness.
* Positive test for hepatitis B or C or HIV.
* Prior participation in other research protocols or clinical care in the last year such that radiation exposure is \>15 mSv and participation in this study would require the subject/volunteer to exceed the annual limits.
* Pregnancy or breastfeeding.
* Current or prior history of coagulopathy.
* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
* History of significant drug and/or food allergies, anaphylactic/anaphylactoid reaction to any allergen.
* Contraindication for arterial cannulation.
* Unsuitable veins for repeated venipuncture.
* Any lacunar infarct in a strategically important location known to lead to cognitive impairment such as the thalamus, hippocampus of either hemisphere, or head of the left caudate
* Severe sub-cortical microvascular disease (Fazekas score of 3 for deep white matter hyperintensities) (Fazekas et al. 1987)
* Territorial infarct or macroscopic hemorrhage (\>10 mm)
* Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips or other medical implants that have not been certified for MRI, or history of claustrophobia in MRI
* Observed claustrophobia at screening
* Ferromagnetic foreign bodies, such as metal shrapnel or bullet fragments, need to be considered on an individual basis

Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes